Pay in 4 interest-free payments of $5.07 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Semaglutide currently has a longer track record of insurance formulary placement
Lipid Panel (Total Cholesterol, LDL, HDL, Triglycerides) Why it matters: Many patients initiating GLP-1 therapy have elevated triglycerides or dyslipidemia as part of their broader metabolic picture
PlexusDx compounded medications are not covered by provincial health plans, but they are HSA/FSA eligible for US-based patients
Moreover, as GLP-1 has been implicated in appetite regulation, measuring its levels can provide valuable insights into the mechanisms of obesity and the effectiveness of weight loss therapies
This table from the National Kidney Foundation shows how they can both be considered: They found that while there was a short drop (eGFR got worse) in the semaglutide group at treatment onset, it came back up and no difference in Cr-eGFR between the semaglutide and placebo groups was observed at week 24. In terms of body weight they found that No correlations were observed between changes in body weight and eGFR during 24-week treatment with semaglutide regardless of whether eGFR was estimated with creatinine or cystatin C or measured with iohexol clearance. They go on to point out that this is a consistent finding in trials of GLP-1 drugs and eGFR
US$ 23.40
US$ 20.27
US$ 24.22
US$ 24.45
US$ 26.01
US$ 28.38
US$ 25.59
